Related Experiment Video
Updated: May 26, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
Published on: January 29, 2019
Targeted alpha therapy with 213Bi
Alfred Morgenstern1, Frank Bruchertseifer, Christos Apostolidis
1European Commission, Joint Research Centre, Institute for Transuranium Elements, PO Box 2340, 76125 Karlsruhe, Germany. alfred.morgenstern@ec.europa.eu
Abstract:
The potential of targeted therapy with the alpha emitter 213Bi has been successfully demonstrated in a large number of preclinical studies and several clinical trials have provided evidence for its feasibility, safety and therapeutic efficacy. This review describes methods for the production of 225Ac and 225Ac/213Bi radionuclide generators, gives an overview of selected preclinical studies and summarizes the current clinical experience with 213Bi.
More Related Videos
10:47Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
Published on: February 3, 2015
09:49A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
Published on: April 24, 2020
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...